Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.
Entrepreneurship needs broader encouragement, and is targeted in a new plan.
BioCrossroads Inc. has raised an $8.25 million seed fund in its second attempt to help startup life sciences companies grow to the point where they can attract venture capital or a corporate funder.
Indiana-based orthopedic implant maker Zimmer Holdings Inc. on Thursday reported a fractional increase in first-quarter profit on higher sales in all global regions, particularly the Asia Pacific.
Sales at Indianapolis-based Dow AgroSciences grew 14 percent in the first quarter, to $1.8 billion, helped by an early planting season in North America and a buoyant agricultural market.
The $38 million Lyles-Porter Hall will house numerous health programs. Purdue also is planning a $25 million Drug Discovery Building that will bring together pharmaceutical researchers from throughout the school.
Bloomington-based medical device maker Cook Group has acquired General BioTechnology LLC, an Indianapolis biotech company with about 20 employees, Cook Group announced Monday.
Eli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
Warsaw-based Biomet, which designs and manufactures orthopedic products for surgical and non-surgical uses, said the deal would greatly expand its sports, extremities and trauma business.
Roche Diagnostics Corp. plans to eliminate about 80 information technology jobs at its Indianapolis-area campus over the next two years, the company said Thursday morning.
Indiana-based Biomet Inc. has agreed to pay $22.7 million to settle U.S. criminal and civil allegations that it bribed government-employed doctors in Argentina, Brazil and China for eight years to win business with hospitals.
Tino Pereira, CEO of Canada-based Iotron Industries, discussed the electron-beam facility his company opened March 15 in Columbia City, which lies halfway between Fort Wayne and Warsaw in northern Indiana. Iotron already helps some of the orthopedic implant makers in Warsaw alter the strength, flexibility or surface conditions of the materials in the joint replacements they make. That makes its services important in research and development for new products.
European regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
Noblesville-based Helmer Inc. said it will invest $10.6 million to build a new manufacturing and headquarters facility at the Saxony Corporate Campus near Interstate 69. It plans to add the jobs by 2014.
Endocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after the European Commission granted it orphan drug status.
The promotions of several executives follow the Indianapolis-based clinical testing company’s announcement in January that it was cutting jobs and restructuring its business.
Architects were told to push the envelope and integrate. Be mindful of where you are in the city and integrate well.
We hate to think what Indiana’s economic future might be if no one had made a point of putting the state’s life sciences assets to work in a coordinated, strategic way.
In the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies, an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national reports on life sciences.
Indiana companies landed just $14.1 million in venture funding last year, the lowest amount of capital flowing to the state’s health care sector since BioEnterprises began tracking such deals in 2005.
